Smith S, Rinehart J S, Ruddock V E, Schiff I
Obstet Gynecol. 1987 Jul;70(1):37-43.
A double-blind, placebo-controlled, randomized multiple crossover study was designed to determine the effectiveness of alprazolam in the treatment of premenstrual syndrome. Patients maintained daily diaries of 22 premenstrual symptoms for one pretreatment control cycle and four treatment cycles. Alprazolam 0.25 mg or placebo was administered three times daily from cycle day 20 until the second day of menstruation, at which time the dosage was tapered by one tablet per day to minimize withdrawal effects. The results of the clinical trial indicate that alprazolam is significantly more effective than placebo in relieving the severity of premenstrual nervous tension, mood swings, irritability, anxiety, depression, fatigue, forgetfulness, crying, cravings for sweets, abdominal bloating, abdominal cramps, and headache. The low incidence of side effects makes alprazolam an acceptable treatment for premenstrual syndrome for those women unresponsive to other therapies.
一项双盲、安慰剂对照、随机多次交叉研究旨在确定阿普唑仑治疗经前综合征的有效性。患者在一个预处理对照周期和四个治疗周期内，每天记录22种经前症状。从周期第20天至月经第二天，每天三次服用0.25毫克阿普唑仑或安慰剂，此时剂量每天减少一片以尽量减少戒断效应。临床试验结果表明，在缓解经前神经紧张、情绪波动、易怒、焦虑、抑郁、疲劳、健忘、哭泣、对甜食的渴望、腹胀、腹部绞痛和头痛的严重程度方面，阿普唑仑比安慰剂显著更有效。副作用发生率低，使阿普唑仑成为对其他疗法无反应的女性经前综合征的可接受治疗方法。
